公开(公告)号：US10233179B2

公开(公告)日：2019-03-19

申请号：US14786454

申请日：2014-04-22

Applicant: AbbVie Inc.

Inventor： Iok Chan Ng ,  M-akhteruzzaman Molla ,  Tami J. Pilot-Matias ,  Anil Vasudevan ,  Tatyana Dekhtyar ,  Artour Gomtsian ,  Kathy Sarris ,  Ana Aguirre ,  Mikhail Chafeev

IPC: C07D417/14 ,  C07D403/14 ,  A61K45/06 ,  A61K31/4178 ,  A61K31/427 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/501 ,  A61K31/506

Abstract: This disclosure relates to: (a) compounds and salts thereof that, inter alia, inhibit RSV infection and/or replication; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

公开(公告)号：US20200222397A1

公开(公告)日：2020-07-16

申请号：US16635813

申请日：2018-07-20

Applicant: AbbVie Inc.

Inventor： Christine Collins ,  Bo Fu ,  Abhishek Gulati ,  Jens Kort ,  Matthew Kosloski ,  Yang Lei ,  Chih-Wei Lin ,  Ran Liu ,  Federico Mensa ,  Iok Chan Ng ,  Tami Pilot-Matias ,  David Pugatch ,  Nancy S. Shulman ,  Roger Trinh ,  Rolando M. Viani ,  Stanley Wang ,  Zhenzhen Zhang

IPC: A61K31/4985 ,  A61K31/454 ,  A61K31/7072 ,  A61K31/498

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 16 weeks, alternatively no more than 12 weeks, or alternatively no more than 8 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 16, 12, or 8 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20200368229A9

公开(公告)日：2020-11-26

申请号：US15667212

申请日：2017-08-02

Applicant: AbbVie Inc.

Inventor： Christine Collins ,  Bo Fu ,  Abhishek Gulati ,  Jens Kort ,  Matthew Kosloski ,  Yang Lei ,  Chih-Wei Lin ,  Ran Liu ,  Federico Mensa ,  Iok Chan Ng ,  Tami Pilot-Matias ,  David Pugatch ,  Nancy S. Shulman ,  Roger Trinh ,  Rolando M. Viani ,  Stanley Wang ,  Zhenzhen Zhang

IPC: A61K31/4985 ,  A61K31/454

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20200330460A1

公开(公告)日：2020-10-22

申请号：US16643069

申请日：2018-08-30

Applicant: AbbVie Inc.

Inventor： Christine Collins ,  Emily O. Dumas ,  Bo Fu ,  Abhishek Gulati ,  Yiran Bonnie Hu ,  Jens Kort ,  Matthew Kosloski ,  Preethi Krishnan ,  Yang Lei ,  Chih-Wei Lin ,  Ran Liu ,  Frederico Mensa ,  Iok Chan Ng ,  Tami Pilot-Matias ,  David Pugatch ,  Susan Rhee ,  Nancy S. Shulman ,  Roger Trinh ,  Rolando M. Viani ,  Stanley Wang ,  Zhenzhan Zhang

IPC: A61K31/4985 ,  A61K31/454 ,  A61K31/7072 ,  A61K31/498

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20160068521A1

公开(公告)日：2016-03-10

申请号：US14786454

申请日：2014-04-22

Applicant: ABBVIE INC.

Inventor： Iok Chan Ng ,  M-akhteruzzaman Molla ,  Tami J. Pilot-Matias ,  Anil Vasudevan ,  Tatyana Dekhtyar ,  Artour Gomtsian ,  Katerina Sarris ,  Ana Aguirre ,  Mikhail Chafeev

IPC: C07D417/14 ,  A61K31/506 ,  A61K31/501 ,  A61K31/4178 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/427 ,  C07D403/14

CPC classification number: C07D417/14 ,  A61K31/4178 ,  A61K31/427 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/501 ,  A61K31/506 ,  A61K45/06 ,  C07D403/14

Abstract: This disclosure relates to: (a) compounds and salts thereof that, inter alia, inhibit RSV infection and/or replication; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

Abstract translation: 本公开涉及：（a）其特别是抑制RSV感染和/或复制的化合物及其盐; （b）可用于制备这些化合物和盐的中间体; （c）包含这些化合物和盐的组合物; （d）制备这种中间体，化合物，盐和组合物的方法; （e）使用这些化合物，盐和组合物的方法; 和（f）包含这些化合物，盐和组合物的试剂盒。

公开(公告)号：US10112911B2

公开(公告)日：2018-10-30

申请号：US14410952

申请日：2013-06-28

Applicant: Abbvie Inc

Inventor： Artour Gomtsian ,  Tatyana Dekhtyar ,  Kristine E. Frank ,  Michael M. Friedman ,  Nathan Josephsohn ,  M-Akhteruzzaman Molla ,  Anil Vasudevan ,  Iok Chan Ng ,  Mikhail Chafeev

IPC: A61K31/495 ,  A61K31/497 ,  C07D241/04 ,  C07D241/26 ,  A61K31/498 ,  C07D413/04 ,  A61K31/496 ,  A61K31/517 ,  C07D487/04 ,  A61K31/519 ,  C07D405/14 ,  C07D403/14 ,  A61K31/499 ,  A61K31/5377 ,  A61K31/4985 ,  C07D401/14 ,  C07D401/04 ,  C07D403/04 ,  C07D405/04 ,  C07D417/04 ,  C07D241/44 ,  C07D471/04 ,  C07D317/66 ,  C07D231/40 ,  C07C335/30

Abstract: This disclosure relates to: (a) compounds and salts of formula (I), formula (II), formula (III), and formula (IV), that, inter alia, inhibit RSV infection and/or replication; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

公开(公告)号：US20170360783A1

公开(公告)日：2017-12-21

申请号：US15693963

申请日：2017-09-01

Applicant: AbbVie Inc.

Inventor： Christine Collins ,  Emily O. Dumas ,  Bo Fu ,  Abhishek Gulati ,  Yiran Bonnie Hu ,  Jens Kort ,  Matthew Kosloski ,  Preethi Krishnan ,  Yang Lei ,  Chih-Wei Lin ,  Ran Liu ,  Federico Mensa ,  Iok Chan Ng ,  Tami Pilot-Matias ,  David Pugatch ,  Susan Rhee ,  Nancy S. Shulman ,  Roger Trinh ,  Rolado M. Viani ,  Stanley Wang ,  Zhenzhen Zhang

IPC: A61K31/4985 ,  A61K31/454

CPC classification number: A61K31/4985 ,  A61K31/454 ,  A61K31/498 ,  A61K31/7072 ,  A61K2300/00

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 16 weeks, alternatively no more than 12 weeks, or alternatively no more than 8 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 16, 12, or 8 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20170333428A1

公开(公告)日：2017-11-23

申请号：US15667212

申请日：2017-08-02

Applicant: AbbVie Inc.

Inventor： Christine Collins ,  Bo Fu ,  Abhishek Gulati ,  Jens Kort ,  Matthew Kosloski ,  Yang Lei ,  Chih-Wei Lin ,  Ran Liu ,  Federico Mensa ,  Iok Chan Ng ,  Tami Pilot-Matias ,  David Pugatch ,  Nancy S. Shulman ,  Rogert Trinh ,  Rolando M. Viani ,  Stanley Wang ,  Zhenzhen Zhang

IPC: A61K31/4985 ,  A61K31/454

CPC classification number: A61K31/4985 ,  A61K31/454 ,  A61K31/498 ,  A61K31/7072 ,  A61K2300/00

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

公开(公告)号：US09447051B2

公开(公告)日：2016-09-20

申请号：US14379155

申请日：2013-02-15

Applicant: AbbVie inc.

Inventor： Tatyana Dekhtyar ,  Arthur Gomtsyan ,  M-Akhteruzzaman Molla ,  Anil Vasudevan ,  Iok Chan Ng ,  Mikhail Chafeev

IPC: C07D239/32 ,  A61K31/505 ,  C07D239/48 ,  C07D403/12 ,  C07D401/14 ,  C07D405/14 ,  C07D401/12 ,  C07D409/14 ,  C07D413/12 ,  C07D417/14 ,  A61K45/06 ,  A61K31/506 ,  C07D413/14

CPC classification number: C07D239/48 ,  A61K31/505 ,  A61K31/506 ,  A61K45/06 ,  C07D239/32 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/14

Abstract: This disclosure relates to: (a) compounds and salts thereof that, inter alia, inhibit RSV infection and/or replication; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.